APA (7th ed.) Citation

Egea‐Rodriguez, S., Váraljai, R., Nordmann, T. M., Lubis, R., Philip, M., Rambow, F., . . . Helfrich, I. RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma. Wiley.

Chicago Style (17th ed.) Citation

Egea‐Rodriguez, Sara, et al. RECQL4 Affects MHC Class II‐mediated Signalling and Favours an Immune‐evasive Signature That Limits Response to Immune Checkpoint Inhibitor Therapy in Patients with Malignant Melanoma. Wiley.

MLA (9th ed.) Citation

Egea‐Rodriguez, Sara, et al. RECQL4 Affects MHC Class II‐mediated Signalling and Favours an Immune‐evasive Signature That Limits Response to Immune Checkpoint Inhibitor Therapy in Patients with Malignant Melanoma. Wiley.